1. Home
  2. LEGN vs BCC Comparison

LEGN vs BCC Comparison

Compare LEGN & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • BCC
  • Stock Information
  • Founded
  • LEGN 2014
  • BCC 2004
  • Country
  • LEGN United States
  • BCC United States
  • Employees
  • LEGN N/A
  • BCC N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • BCC RETAIL: Building Materials
  • Sector
  • LEGN Health Care
  • BCC Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • BCC Nasdaq
  • Market Cap
  • LEGN 6.0B
  • BCC 4.9B
  • IPO Year
  • LEGN 2020
  • BCC 2013
  • Fundamental
  • Price
  • LEGN $32.66
  • BCC $127.95
  • Analyst Decision
  • LEGN Strong Buy
  • BCC Buy
  • Analyst Count
  • LEGN 13
  • BCC 5
  • Target Price
  • LEGN $80.62
  • BCC $139.60
  • AVG Volume (30 Days)
  • LEGN 1.3M
  • BCC 387.5K
  • Earning Date
  • LEGN 03-10-2025
  • BCC 02-18-2025
  • Dividend Yield
  • LEGN N/A
  • BCC 4.55%
  • EPS Growth
  • LEGN N/A
  • BCC N/A
  • EPS
  • LEGN N/A
  • BCC 10.21
  • Revenue
  • LEGN $520,183,000.00
  • BCC $6,801,070,000.00
  • Revenue This Year
  • LEGN $120.36
  • BCC N/A
  • Revenue Next Year
  • LEGN $67.91
  • BCC $5.04
  • P/E Ratio
  • LEGN N/A
  • BCC $12.53
  • Revenue Growth
  • LEGN 122.96
  • BCC N/A
  • 52 Week Low
  • LEGN $30.17
  • BCC $113.38
  • 52 Week High
  • LEGN $70.13
  • BCC $155.42
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.28
  • BCC 52.87
  • Support Level
  • LEGN $30.17
  • BCC $113.38
  • Resistance Level
  • LEGN $37.92
  • BCC $122.00
  • Average True Range (ATR)
  • LEGN 2.07
  • BCC 3.05
  • MACD
  • LEGN 0.12
  • BCC 1.76
  • Stochastic Oscillator
  • LEGN 32.13
  • BCC 86.29

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: